Clinical and Microbiological Characteristics of Proven Invasive Aspergillosis Due to Rare/Cryptic Species in Allogeneic Hematopoietic Stem Cell Transplant Recipients
There are few reports on the clinical course of proven invasive aspergillosis (IA) due to rare/cryptic species in allogeneic hematopoietic stem cell transplant (allo-HSCT) recipients. We retrospectively reviewed the electronic medical records of patients who underwent allo-HSCT between January 2012...
Saved in:
Published in | Antimicrobial agents and chemotherapy Vol. 66; no. 1; p. e0163021 |
---|---|
Main Authors | , , , , , , , , , , , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
American Society for Microbiology
18.01.2022
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | There are few reports on the clinical course of proven invasive aspergillosis (IA) due to rare/cryptic species in allogeneic hematopoietic stem cell transplant (allo-HSCT) recipients. We retrospectively reviewed the electronic medical records of patients who underwent allo-HSCT between January 2012 and December 2018.
There are few reports on the clinical course of proven invasive aspergillosis (IA) due to rare/cryptic species in allogeneic hematopoietic stem cell transplant (allo-HSCT) recipients. We retrospectively reviewed the electronic medical records of patients who underwent allo-HSCT between January 2012 and December 2018. Of 934 allo-HSCT recipients, 10 were diagnosed with proven IA and 61 were diagnosed with probable IA. DNA sequencing was performed in cases of proven IA, and
Aspergillus
could be identified to the species level in 8 of the 10 cases. Three were due to
A. fumigatus
, and 5 were due to rare/cryptic
Aspergillus
species, namely,
A. turcosus
,
A. felis
,
A. viridinutans
,
A. nidulans
, and
A. calidoustus
. In these 8 patients, no patients with IA due to
A. fumigatus
died, whereas 3 of the 5 with IA due to rare/cryptic species died within 12 weeks. The 2 surviving cases of IA due to rare/cryptic species were treated with surgical resection and antifungal treatment. Susceptibility testing for cryptic species in 4 cases showed an amphotericin B MIC > 1 mg/L in 3 cases, itraconazole MIC > 1 mg/L in 2 cases, and voriconazole MIC > 1 mg/L in 2 cases. In conclusion, more than half of the causative pathogens of proven IA were rare/cryptic species, so it is important to accurately identify the
Aspergillus
species. In addition, surgical treatment might be an important option in cases of proven IA, given the possibility that the causative organisms are azole-resistant
A. fumigatus
or rare/cryptic species. |
---|---|
AbstractList | There are few reports on the clinical course of proven invasive aspergillosis (IA) due to rare/cryptic species in allogeneic hematopoietic stem cell transplant (allo-HSCT) recipients. We retrospectively reviewed the electronic medical records of patients who underwent allo-HSCT between January 2012 and December 2018. Of 934 allo-HSCT recipients, 10 were diagnosed with proven IA and 61 were diagnosed with probable IA. DNA sequencing was performed in cases of proven IA, and Aspergillus could be identified to the species level in 8 of the 10 cases. Three were due to A. fumigatus, and 5 were due to rare/cryptic Aspergillus species, namely, A. turcosus, A. felis, A. viridinutans, A. nidulans, and A. calidoustus. In these 8 patients, no patients with IA due to A. fumigatus died, whereas 3 of the 5 with IA due to rare/cryptic species died within 12 weeks. The 2 surviving cases of IA due to rare/cryptic species were treated with surgical resection and antifungal treatment. Susceptibility testing for cryptic species in 4 cases showed an amphotericin B MIC > 1 mg/L in 3 cases, itraconazole MIC > 1 mg/L in 2 cases, and voriconazole MIC > 1 mg/L in 2 cases. In conclusion, more than half of the causative pathogens of proven IA were rare/cryptic species, so it is important to accurately identify the Aspergillus species. In addition, surgical treatment might be an important option in cases of proven IA, given the possibility that the causative organisms are azole-resistant A. fumigatus or rare/cryptic species. There are few reports on the clinical course of proven invasive aspergillosis (IA) due to rare/cryptic species in allogeneic hematopoietic stem cell transplant (allo-HSCT) recipients. We retrospectively reviewed the electronic medical records of patients who underwent allo-HSCT between January 2012 and December 2018. Of 934 allo-HSCT recipients, 10 were diagnosed with proven IA and 61 were diagnosed with probable IA. DNA sequencing was performed in cases of proven IA, and Aspergillus could be identified to the species level in 8 of the 10 cases. Three were due to A. fumigatus , and 5 were due to rare/cryptic Aspergillus species, namely, A. turcosus , A. felis , A. viridinutans , A. nidulans , and A. calidoustus . In these 8 patients, no patients with IA due to A. fumigatus died, whereas 3 of the 5 with IA due to rare/cryptic species died within 12 weeks. The 2 surviving cases of IA due to rare/cryptic species were treated with surgical resection and antifungal treatment. Susceptibility testing for cryptic species in 4 cases showed an amphotericin B MIC > 1 mg/L in 3 cases, itraconazole MIC > 1 mg/L in 2 cases, and voriconazole MIC > 1 mg/L in 2 cases. In conclusion, more than half of the causative pathogens of proven IA were rare/cryptic species, so it is important to accurately identify the Aspergillus species. In addition, surgical treatment might be an important option in cases of proven IA, given the possibility that the causative organisms are azole-resistant A. fumigatus or rare/cryptic species. There are few reports on the clinical course of proven invasive aspergillosis (IA) due to rare/cryptic species in allogeneic hematopoietic stem cell transplant (allo-HSCT) recipients. We retrospectively reviewed the electronic medical records of patients who underwent allo-HSCT between January 2012 and December 2018. Of 934 allo-HSCT recipients, 10 were diagnosed with proven IA and 61 were diagnosed with probable IA. DNA sequencing was performed in cases of proven IA, and Aspergillus could be identified to the species level in 8 of the 10 cases. Three were due to A. fumigatus, and 5 were due to rare/cryptic Aspergillus species, namely, , , A. viridinutans, A. nidulans, and A. calidoustus. In these 8 patients, no patients with IA due to A. fumigatus died, whereas 3 of the 5 with IA due to rare/cryptic species died within 12 weeks. The 2 surviving cases of IA due to rare/cryptic species were treated with surgical resection and antifungal treatment. Susceptibility testing for cryptic species in 4 cases showed an amphotericin B MIC > 1 mg/L in 3 cases, itraconazole MIC > 1 mg/L in 2 cases, and voriconazole MIC > 1 mg/L in 2 cases. In conclusion, more than half of the causative pathogens of proven IA were rare/cryptic species, so it is important to accurately identify the Aspergillus species. In addition, surgical treatment might be an important option in cases of proven IA, given the possibility that the causative organisms are azole-resistant A. fumigatus or rare/cryptic species. There are few reports on the clinical course of proven invasive aspergillosis (IA) due to rare/cryptic species in allogeneic hematopoietic stem cell transplant (allo-HSCT) recipients. We retrospectively reviewed the electronic medical records of patients who underwent allo-HSCT between January 2012 and December 2018. Of 934 allo-HSCT recipients, 10 were diagnosed with proven IA and 61 were diagnosed with probable IA. DNA sequencing was performed in cases of proven IA, and Aspergillus could be identified to the species level in 8 of the 10 cases. Three were due to A. fumigatus, and 5 were due to rare/cryptic Aspergillus species, namely, A. turcosus, A. felis, A. viridinutans, A. nidulans, and A. calidoustus. In these 8 patients, no patients with IA due to A. fumigatus died, whereas 3 of the 5 with IA due to rare/cryptic species died within 12 weeks. The 2 surviving cases of IA due to rare/cryptic species were treated with surgical resection and antifungal treatment. Susceptibility testing for cryptic species in 4 cases showed an amphotericin B MIC > 1 mg/L in 3 cases, itraconazole MIC > 1 mg/L in 2 cases, and voriconazole MIC > 1 mg/L in 2 cases. In conclusion, more than half of the causative pathogens of proven IA were rare/cryptic species, so it is important to accurately identify the Aspergillus species. In addition, surgical treatment might be an important option in cases of proven IA, given the possibility that the causative organisms are azole-resistant A. fumigatus or rare/cryptic species.There are few reports on the clinical course of proven invasive aspergillosis (IA) due to rare/cryptic species in allogeneic hematopoietic stem cell transplant (allo-HSCT) recipients. We retrospectively reviewed the electronic medical records of patients who underwent allo-HSCT between January 2012 and December 2018. Of 934 allo-HSCT recipients, 10 were diagnosed with proven IA and 61 were diagnosed with probable IA. DNA sequencing was performed in cases of proven IA, and Aspergillus could be identified to the species level in 8 of the 10 cases. Three were due to A. fumigatus, and 5 were due to rare/cryptic Aspergillus species, namely, A. turcosus, A. felis, A. viridinutans, A. nidulans, and A. calidoustus. In these 8 patients, no patients with IA due to A. fumigatus died, whereas 3 of the 5 with IA due to rare/cryptic species died within 12 weeks. The 2 surviving cases of IA due to rare/cryptic species were treated with surgical resection and antifungal treatment. Susceptibility testing for cryptic species in 4 cases showed an amphotericin B MIC > 1 mg/L in 3 cases, itraconazole MIC > 1 mg/L in 2 cases, and voriconazole MIC > 1 mg/L in 2 cases. In conclusion, more than half of the causative pathogens of proven IA were rare/cryptic species, so it is important to accurately identify the Aspergillus species. In addition, surgical treatment might be an important option in cases of proven IA, given the possibility that the causative organisms are azole-resistant A. fumigatus or rare/cryptic species. There are few reports on the clinical course of proven invasive aspergillosis (IA) due to rare/cryptic species in allogeneic hematopoietic stem cell transplant (allo-HSCT) recipients. We retrospectively reviewed the electronic medical records of patients who underwent allo-HSCT between January 2012 and December 2018. There are few reports on the clinical course of proven invasive aspergillosis (IA) due to rare/cryptic species in allogeneic hematopoietic stem cell transplant (allo-HSCT) recipients. We retrospectively reviewed the electronic medical records of patients who underwent allo-HSCT between January 2012 and December 2018. Of 934 allo-HSCT recipients, 10 were diagnosed with proven IA and 61 were diagnosed with probable IA. DNA sequencing was performed in cases of proven IA, and Aspergillus could be identified to the species level in 8 of the 10 cases. Three were due to A. fumigatus , and 5 were due to rare/cryptic Aspergillus species, namely, A. turcosus , A. felis , A. viridinutans , A. nidulans , and A. calidoustus . In these 8 patients, no patients with IA due to A. fumigatus died, whereas 3 of the 5 with IA due to rare/cryptic species died within 12 weeks. The 2 surviving cases of IA due to rare/cryptic species were treated with surgical resection and antifungal treatment. Susceptibility testing for cryptic species in 4 cases showed an amphotericin B MIC > 1 mg/L in 3 cases, itraconazole MIC > 1 mg/L in 2 cases, and voriconazole MIC > 1 mg/L in 2 cases. In conclusion, more than half of the causative pathogens of proven IA were rare/cryptic species, so it is important to accurately identify the Aspergillus species. In addition, surgical treatment might be an important option in cases of proven IA, given the possibility that the causative organisms are azole-resistant A. fumigatus or rare/cryptic species. |
Author | Asano-Mori, Yuki Miyazaki, Yoshitsugu Yuasa, Mitsuhiro Kaji, Daisuke Yamamuro, Ryosuke Takagi, Shinsuke Umeyama, Takashi Abe, Masahiro Yamamoto, Hisashi Taya, Yuki Ishiwata, Kazuya Araoka, Hideki Nishida, Aya Uchida, Naoyuki Ogura, Sho Yamamoto, Go Yamagoe, Satoshi Wake, Atsushi Mitsuki, Takashi Kageyama, Kosei Taniguchi, Shuichi Nakamura, Shigeki Yamaguchi, Kyosuke Sakoh, Takashi Kimura, Muneyoshi |
Author_xml | – sequence: 1 givenname: Ryosuke orcidid: 0000-0002-3987-9118 surname: Yamamuro fullname: Yamamuro, Ryosuke organization: Department of Infectious Diseases, Toranomon Hospital, Tokyo, Japan – sequence: 2 givenname: Muneyoshi orcidid: 0000-0003-4461-1500 surname: Kimura fullname: Kimura, Muneyoshi organization: Department of Infectious Diseases, Toranomon Hospital, Tokyo, Japan – sequence: 3 givenname: Yuki surname: Asano-Mori fullname: Asano-Mori, Yuki organization: Department of Hematology, Toranomon Hospital, Tokyo, Japan – sequence: 4 givenname: Masahiro surname: Abe fullname: Abe, Masahiro organization: Department of Fungal Infection, National Institute of Infectious Diseases, Tokyo, Japan – sequence: 5 givenname: Shigeki surname: Nakamura fullname: Nakamura, Shigeki organization: Department of Fungal Infection, National Institute of Infectious Diseases, Tokyo, Japan – sequence: 6 givenname: Takashi orcidid: 0000-0002-6635-4288 surname: Umeyama fullname: Umeyama, Takashi organization: Department of Fungal Infection, National Institute of Infectious Diseases, Tokyo, Japan – sequence: 7 givenname: Satoshi surname: Yamagoe fullname: Yamagoe, Satoshi organization: Department of Fungal Infection, National Institute of Infectious Diseases, Tokyo, Japan – sequence: 8 givenname: Yoshitsugu orcidid: 0000-0001-8942-0869 surname: Miyazaki fullname: Miyazaki, Yoshitsugu organization: Department of Fungal Infection, National Institute of Infectious Diseases, Tokyo, Japan – sequence: 9 givenname: Sho surname: Ogura fullname: Ogura, Sho organization: Department of Infectious Diseases, Toranomon Hospital, Tokyo, Japan – sequence: 10 givenname: Takashi surname: Sakoh fullname: Sakoh, Takashi organization: Department of Infectious Diseases, Toranomon Hospital, Tokyo, Japan – sequence: 11 givenname: Takashi surname: Mitsuki fullname: Mitsuki, Takashi organization: Department of Hematology, Toranomon Hospital, Tokyo, Japan – sequence: 12 givenname: Kyosuke surname: Yamaguchi fullname: Yamaguchi, Kyosuke organization: Department of Hematology, Toranomon Hospital, Tokyo, Japan – sequence: 13 givenname: Mitsuhiro surname: Yuasa fullname: Yuasa, Mitsuhiro organization: Department of Hematology, Toranomon Hospital, Tokyo, Japan – sequence: 14 givenname: Daisuke surname: Kaji fullname: Kaji, Daisuke organization: Department of Hematology, Toranomon Hospital, Tokyo, Japan – sequence: 15 givenname: Kosei surname: Kageyama fullname: Kageyama, Kosei organization: Department of Hematology, Toranomon Hospital, Tokyo, Japan – sequence: 16 givenname: Aya surname: Nishida fullname: Nishida, Aya organization: Department of Hematology, Toranomon Hospital, Tokyo, Japan – sequence: 17 givenname: Yuki surname: Taya fullname: Taya, Yuki organization: Department of Hematology, Toranomon Hospital, Tokyo, Japan – sequence: 18 givenname: Kazuya surname: Ishiwata fullname: Ishiwata, Kazuya organization: Department of Hematology, Toranomon Hospital, Tokyo, Japan – sequence: 19 givenname: Shinsuke surname: Takagi fullname: Takagi, Shinsuke organization: Department of Hematology, Toranomon Hospital, Tokyo, Japan – sequence: 20 givenname: Hisashi surname: Yamamoto fullname: Yamamoto, Hisashi organization: Department of Hematology, Toranomon Hospital, Tokyo, Japan – sequence: 21 givenname: Go surname: Yamamoto fullname: Yamamoto, Go organization: Department of Hematology, Toranomon Hospital, Tokyo, Japan – sequence: 22 givenname: Naoyuki surname: Uchida fullname: Uchida, Naoyuki organization: Department of Hematology, Toranomon Hospital, Tokyo, Japan, Okinaka Memorial Institute for Medical Research, Tokyo, Japan – sequence: 23 givenname: Atsushi surname: Wake fullname: Wake, Atsushi organization: Department of Hematology, Toranomon Hospital, Tokyo, Japan, Okinaka Memorial Institute for Medical Research, Tokyo, Japan – sequence: 24 givenname: Shuichi surname: Taniguchi fullname: Taniguchi, Shuichi organization: Department of Hematology, Toranomon Hospital, Tokyo, Japan, Okinaka Memorial Institute for Medical Research, Tokyo, Japan – sequence: 25 givenname: Hideki orcidid: 0000-0002-3349-9296 surname: Araoka fullname: Araoka, Hideki organization: Department of Infectious Diseases, Toranomon Hospital, Tokyo, Japan, Okinaka Memorial Institute for Medical Research, Tokyo, Japan |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/34780271$$D View this record in MEDLINE/PubMed |
BookMark | eNp1kUtv1DAUhS1URKeFHWvkJUhNazsvZ4MUhUcrFYFKWVs3yZ2pK8dObc9I_UH8z3pmWgQIVpavv3N8rs4RObDOIiGvOTvlXMiztu1OGa9ylgn-jCw4a2RWlU11QBaMVVVWSFYckqMQblm6lw17QQ7zopZM1HxBfnZGWz2AoWBH-kUP3vXaGbfazbob8DBE9DpEPQTqlvSbdxu09MJuIOgN0jbM6FfaGBd0oB_WSKOjV-DxrPP3c1LR7zMOGgPVlrYJW6HFND3HCaKbncYdE3GiHRpDrz3YMBuwkV4l3azRxvCSPF-CCfjq8TwmPz59vO7Os8uvny-69jKDQhYxq3jf5GXBSjaIsejrpodSctEwDn1d8brvq2pkjYC6ycW4zEGyno1jKXAphcQmPybv977zup9wHNLfHoyavZ7A3ysHWv35YvWNWrmNknVV5iJPBm8fDby7W2OIatJhSHuBRbcOSpSNZHVZ1zyh7_YohEmoW7f2Nq2mOFPbWlWqVe1qVWLLvvk9169ATz0mQOyB1F8IHpdq0BGidtuY2vzP9eQv0ZPvP_EHL-rBCA |
CitedBy_id | crossref_primary_10_1128_cmr_00015_23 crossref_primary_10_1128_aac_02206_21 crossref_primary_10_1128_aac_02368_21 crossref_primary_10_3390_jof9060628 crossref_primary_10_1128_cmr_00099_22 |
Cites_doi | 10.1016/j.ijid.2012.09.004 10.1128/JCM.00535-08 10.1007/s11046-014-9775-z 10.1128/EC.4.3.625-632.2005 10.1016/j.simyco.2020.05.002 10.1128/AAC.00383-13 10.1016/j.jiac.2018.10.016 10.1093/cid/ciy859 10.1200/JCO.18.00374 10.1128/JCM.01070-09 10.1128/JCM.02023-18 10.1111/myc.13158 10.3201/eid2009.140142 10.1128/AAC.05394-11 10.1378/chest.126.6.1783 10.1086/651263 10.1128/JCM.01582-14 10.1093/mmy/myx067 10.3389/fmicb.2018.01656 10.1093/cid/ciz1008 10.1182/blood-2005-02-0733 10.1093/jac/dkq279 10.1128/AAC.00692-10 |
ContentType | Journal Article |
Copyright | Copyright © 2022 American Society for Microbiology. Copyright © 2022 American Society for Microbiology. 2022 American Society for Microbiology |
Copyright_xml | – notice: Copyright © 2022 American Society for Microbiology. – notice: Copyright © 2022 American Society for Microbiology. 2022 American Society for Microbiology |
DBID | AAYXX CITATION NPM 7X8 5PM |
DOI | 10.1128/AAC.01630-21 |
DatabaseName | CrossRef PubMed MEDLINE - Academic PubMed Central (Full Participant titles) |
DatabaseTitle | CrossRef PubMed MEDLINE - Academic |
DatabaseTitleList | PubMed MEDLINE - Academic CrossRef |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine Biology Pharmacy, Therapeutics, & Pharmacology |
EISSN | 1098-6596 |
ExternalDocumentID | PMC8765323 01630-21 34780271 10_1128_AAC_01630_21 |
Genre | Research Support, Non-U.S. Gov't Journal Article |
GrantInformation_xml | – fundername: Japan Agency for Medical Research and Development (AMED) grantid: JP21fk0108094 funderid: https://doi.org/10.13039/100009619 – fundername: ; grantid: JP21fk0108094 |
GroupedDBID | --- .55 0R~ 23M 2WC 39C 4.4 53G 5GY 5RE 5VS 6J9 AAGFI AAYXX ACGFO ADBBV AENEX AGVNZ ALMA_UNASSIGNED_HOLDINGS AOIJS BAWUL BTFSW CITATION CS3 DIK E3Z EBS F5P FRP GX1 H13 HH5 HYE HZ~ H~9 K-O KQ8 L7B LSO O9- OK1 P2P RHI RNS RPM RSF TR2 UHB W2D W8F WH7 WOQ X7M NPM RHF - 0R 55 AAPBV ABFLS ADACO BXI HZ ZA5 7X8 5PM |
ID | FETCH-LOGICAL-a484t-61b9354050c2d4b79ba5812901ab7617bb66d092a7932df3a80b0dd52ef828e93 |
ISSN | 0066-4804 1098-6596 |
IngestDate | Thu Aug 21 13:46:45 EDT 2025 Fri Jul 11 09:51:25 EDT 2025 Tue Jan 18 18:30:17 EST 2022 Thu Jan 02 22:54:43 EST 2025 Thu Apr 24 23:05:23 EDT 2025 Tue Jul 01 04:13:26 EDT 2025 |
IsDoiOpenAccess | false |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 1 |
Keywords | rare species invasive aspergillosis allogeneic hematopoietic stem cell transplant recipients proven invasive aspergillosis cryptic species |
Language | English |
License | All Rights Reserved. https://doi.org/10.1128/ASMCopyrightv2 All Rights Reserved. |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-a484t-61b9354050c2d4b79ba5812901ab7617bb66d092a7932df3a80b0dd52ef828e93 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 The authors declare no conflict of interest. |
ORCID | 0000-0002-6635-4288 0000-0003-4461-1500 0000-0002-3987-9118 0000-0002-3349-9296 0000-0001-8942-0869 |
OpenAccessLink | https://www.ncbi.nlm.nih.gov/pmc/articles/8765323 |
PMID | 34780271 |
PQID | 2598075771 |
PQPubID | 23479 |
PageCount | 6 |
ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_8765323 proquest_miscellaneous_2598075771 asm2_journals_10_1128_AAC_01630_21 pubmed_primary_34780271 crossref_citationtrail_10_1128_AAC_01630_21 crossref_primary_10_1128_AAC_01630_21 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 20220118 |
PublicationDateYYYYMMDD | 2022-01-18 |
PublicationDate_xml | – month: 1 year: 2022 text: 20220118 day: 18 |
PublicationDecade | 2020 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States – name: 1752 N St., N.W., Washington, DC |
PublicationTitle | Antimicrobial agents and chemotherapy |
PublicationTitleAbbrev | Antimicrob Agents Chemother |
PublicationTitleAlternate | Antimicrob Agents Chemother |
PublicationYear | 2022 |
Publisher | American Society for Microbiology |
Publisher_xml | – name: American Society for Microbiology |
References | e_1_3_3_6_2 e_1_3_3_5_2 e_1_3_3_8_2 e_1_3_3_7_2 Anonymous (e_1_3_3_12_2) 2008 e_1_3_3_17_2 e_1_3_3_9_2 e_1_3_3_16_2 e_1_3_3_19_2 e_1_3_3_18_2 e_1_3_3_13_2 e_1_3_3_24_2 e_1_3_3_23_2 e_1_3_3_15_2 e_1_3_3_14_2 e_1_3_3_25_2 e_1_3_3_2_2 e_1_3_3_20_2 e_1_3_3_4_2 e_1_3_3_11_2 e_1_3_3_22_2 e_1_3_3_3_2 e_1_3_3_10_2 e_1_3_3_21_2 Houbraken, J, Kocsube, S, Visagie, CM, Yilmaz, N, Wang, XC, Meijer, M, Kraak, B, Hubka, V, Bensch, K, Samson, RA, Frisvad, JC (B2) 2020; 95 Racil, Z, Weinbergerova, B, Kocmanova, I, Muzik, J, Kouba, M, Drgona, L, Masarova, L, Guman, T, Tothova, E, Forsterova, K, Haber, J, Ziakova, B, Bojtarova, E, Vydra, J, Mudry, P, Foralova, R, Sejnova, D, Mallatova, N, Kandrnal, V, Cetkovsky, P, Mayer, J (B19) 2013; 17 Tsang, CC, Tang, JYM, Ye, H, Xing, F, Lo, SKF, Xiao, C, Han, L, Wu, AKL, Ngan, AHY, Law, KC, To, YN, Sze, DTT, Chim, OHY, Hui, TWS, Leung, CWH, Zhu, T, Yao, C, Tse, BPH, Lau, SKP, Woo, PCY (B4) 2020; 63 Negri, CE, Goncalves, SS, Xafranski, H, Bergamasco, MD, Aquino, VR, Castro, PT, Colombo, AL (B5) 2014; 52 Pinto, E, Monteiro, C, Maia, M, Faria, MA, Lopes, V, Lameiras, C, Pinheiro, D (B14) 2018; 9 Pfaller, MA, Messer, SA, Boyken, L, Rice, C, Tendolkar, S, Hollis, RJ, Diekema, DJ (B24) 2008; 46 Balajee, SA, Kano, R, Baddley, JW, Moser, SA, Marr, KA, Alexander, BD, Andes, D, Kontoyiannis, DP, Perrone, G, Peterson, S, Brandt, ME, Pappas, PG, Chiller, T (B3) 2009; 47 Alastruey-Izquierdo, A, Alcazar-Fuoli, L, Cuenca-Estrella, M (B7) 2014; 178 Bueid, A, Howard, SJ, Moore, CB, Richardson, MD, Harrison, E, Bowyer, P, Denning, DW (B15) 2010; 65 Kontoyiannis, DP, Marr, KA, Park, BJ, Alexander, BD, Anaissie, EJ, Walsh, TJ, Ito, J, Andes, DR, Baddley, JW, Brown, JM, Brumble, LM, Freifeld, AG, Hadley, S, Herwaldt, LA, Kauffman, CA, Knapp, K, Lyon, GM, Morrison, VA, Papanicolaou, G, Patterson, TF, Perl, TM, Schuster, MG, Walker, R, Wannemuehler, KA, Wingard, JR, Chiller, TM, Pappas, PG (B1) 2010; 50 Yamairi, K, Ido, K, Nakamura, S, Niki, M, Imoto, W, Shibata, W, Namikawa, H, Fujimoto, H, Yamada, K, Nakamae, H, Hino, M, Kaneko, Y, Miyazaki, Y, Kakeya, H (B8) 2019; 25 Alastruey-Izquierdo, A, Mellado, E, Pelaez, T, Peman, J, Zapico, S, Alvarez, M, Rodriguez-Tudela, JL, Cuenca-Estrella, M, Group, FS (B13) 2013; 57 (B11) 2008 Lestrade, PP, Bentvelsen, RG, Schauwvlieghe, A, Schalekamp, S, van der Velden, W, Kuiper, EJ, van Paassen, J, van der Hoven, B, van der Lee, HA, Melchers, WJG, de Haan, AF, van der Hoeven, HL, Rijnders, BJA, van der Beek, MT, Verweij, PE (B22) 2019; 68 Donnelly, JP, Chen, SC, Kauffman, CA, Steinbach, WJ, Baddley, JW, Verweij, PE, Clancy, CJ, Wingard, JR, Lockhart, SR, Groll, AH, Sorrell, TC, Bassetti, M, Akan, H, Alexander, BD, Andes, D, Azoulay, E, Bialek, R, Bradsher, RW, Bretagne, S, Calandra, T, Caliendo, AM, Castagnola, E, Cruciani, M, Cuenca-Estrella, M, Decker, CF, Desai, SR, Fisher, B, Harrison, T, Heussel, CP, Jensen, HE, Kibbler, CC, Kontoyiannis, DP, Kullberg, BJ, Lagrou, K, Lamoth, F, Lehrnbecher, T, Loeffler, J, Lortholary, O, Maertens, J, Marchetti, O, Marr, KA, Masur, H, Meis, JF, Morrisey, CO, Nucci, M, Ostrosky-Zeichner, L, Pagano, L, Patterson, TF, Perfect, JR, Racil, Z (B9) 2020; 71 Cho, SY, Lee, DG, Kim, WB, Chun, HS, Park, C, Myong, JP, Park, YJ, Choi, JK, Lee, HJ, Kim, SH, Park, SH, Choi, SM, Choi, JH, Yoo, JH (B12) 2019; 57 Pham, CD, Reiss, E, Hagen, F, Meis, JF, Lockhart, SR (B17) 2014; 20 Matt, P, Bernet, F, Habicht, J, Gambazzi, F, Gratwohl, A, Zerkowski, HR, Tamm, M (B21) 2004; 126 Schwartz, S, Ruhnke, M, Ribaud, P, Corey, L, Driscoll, T, Cornely, OA, Schuler, U, Lutsar, I, Troke, P, Thiel, E (B20) 2005; 106 Mortensen, KL, Mellado, E, Lass-Florl, C, Rodriguez-Tudela, JL, Johansen, HK, Arendrup, MC (B16) 2010; 54 Taplitz, RA, Kennedy, EB, Bow, EJ, Crews, J, Gleason, C, Hawley, DK, Langston, AA, Nastoupil, LJ, Rajotte, M, Rolston, KV, Strasfeld, L, Flowers, CR (B23) 2018; 36 Balajee, SA, Gribskov, JL, Hanley, E, Nickle, D, Marr, KA (B10) 2005; 4 Tashiro, M, Izumikawa, K, Minematsu, A, Hirano, K, Iwanaga, N, Ide, S, Mihara, T, Hosogaya, N, Takazono, T, Morinaga, Y, Nakamura, S, Kurihara, S, Imamura, Y, Miyazaki, T, Nishino, T, Tsukamoto, M, Kakeya, H, Yamamoto, Y, Yanagihara, K, Yasuoka, A, Tashiro, T, Kohno, S (B18) 2012; 56 Won, EJ, Shin, JH, Kim, SH, Choi, MJ, Byun, SA, Kim, MN, Lee, WG, Lee, K, Uh, Y, Shin, MG, Suh, SP (B6) 2018; 56 |
References_xml | – ident: e_1_3_3_20_2 doi: 10.1016/j.ijid.2012.09.004 – ident: e_1_3_3_25_2 doi: 10.1128/JCM.00535-08 – ident: e_1_3_3_8_2 doi: 10.1007/s11046-014-9775-z – ident: e_1_3_3_11_2 doi: 10.1128/EC.4.3.625-632.2005 – ident: e_1_3_3_3_2 doi: 10.1016/j.simyco.2020.05.002 – ident: e_1_3_3_14_2 doi: 10.1128/AAC.00383-13 – ident: e_1_3_3_9_2 doi: 10.1016/j.jiac.2018.10.016 – ident: e_1_3_3_23_2 doi: 10.1093/cid/ciy859 – ident: e_1_3_3_24_2 doi: 10.1200/JCO.18.00374 – ident: e_1_3_3_4_2 doi: 10.1128/JCM.01070-09 – ident: e_1_3_3_13_2 doi: 10.1128/JCM.02023-18 – ident: e_1_3_3_5_2 doi: 10.1111/myc.13158 – ident: e_1_3_3_18_2 doi: 10.3201/eid2009.140142 – ident: e_1_3_3_19_2 doi: 10.1128/AAC.05394-11 – ident: e_1_3_3_22_2 doi: 10.1378/chest.126.6.1783 – ident: e_1_3_3_2_2 doi: 10.1086/651263 – ident: e_1_3_3_6_2 doi: 10.1128/JCM.01582-14 – ident: e_1_3_3_7_2 doi: 10.1093/mmy/myx067 – ident: e_1_3_3_15_2 doi: 10.3389/fmicb.2018.01656 – ident: e_1_3_3_10_2 doi: 10.1093/cid/ciz1008 – volume-title: CLSI. reference method for broth dilution antifungal susceptibility testing of filamentous fungi; approved standard year: 2008 ident: e_1_3_3_12_2 – ident: e_1_3_3_21_2 doi: 10.1182/blood-2005-02-0733 – ident: e_1_3_3_16_2 doi: 10.1093/jac/dkq279 – ident: e_1_3_3_17_2 doi: 10.1128/AAC.00692-10 – volume: 50 start-page: 1091 year: 2010 end-page: 1100 ident: B1 article-title: Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001–2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) database publication-title: Clin Infect Dis doi: 10.1086/651263 – volume: 95 start-page: 5 year: 2020 end-page: 169 ident: B2 article-title: Classification of Aspergillus, Penicillium, Talaromyces and related genera (Eurotiales): an overview of families, genera, subgenera, sections, series and species publication-title: Stud Mycol doi: 10.1016/j.simyco.2020.05.002 – volume: 36 start-page: 3043 year: 2018 end-page: 3054 ident: B23 article-title: Antimicrobial prophylaxis for adult patients with cancer-related immunosuppression: ASCO and IDSA Clinical Practice Guideline update publication-title: J Clin Oncol doi: 10.1200/JCO.18.00374 – volume: 54 start-page: 4545 year: 2010 end-page: 4549 ident: B16 article-title: Environmental study of azole-resistant Aspergillus fumigatus and other aspergilli in Austria, Denmark, and Spain publication-title: Antimicrob Agents Chemother doi: 10.1128/AAC.00692-10 – volume: 20 start-page: 1498 year: 2014 end-page: 1503 ident: B17 article-title: Passive surveillance for azole-resistant Aspergillus fumigatus, United States, 2011–2013 publication-title: Emerg Infect Dis doi: 10.3201/eid2009.140142 – volume: 71 start-page: 1367 year: 2020 end-page: 1376 ident: B9 article-title: Revision and update of the consensus definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium publication-title: Clin Infect Dis doi: 10.1093/cid/ciz1008 – volume: 57 year: 2019 ident: B12 article-title: Epidemiology and antifungal susceptibility profile of Aspergillus species: comparison between environmental and clinical isolates from patients with hematologic malignancies publication-title: J Clin Microbiol doi: 10.1128/JCM.02023-18 – volume: 17 start-page: e101 year: 2013 end-page: 109 ident: B19 article-title: Invasive aspergillosis in patients with hematological malignancies in the Czech and Slovak republics: Fungal InfectioN Database (FIND) analysis, 2005–2009 publication-title: Int J Infect Dis doi: 10.1016/j.ijid.2012.09.004 – volume: 68 start-page: 1463 year: 2019 end-page: 1471 ident: B22 article-title: Voriconazole resistance and mortality in invasive aspergillosis: a multicenter retrospective cohort study publication-title: Clin Infect Dis doi: 10.1093/cid/ciy859 – volume: 126 start-page: 1783 year: 2004 end-page: 1788 ident: B21 article-title: Predicting outcome after lung resection for invasive pulmonary aspergillosis in patients with neutropenia publication-title: Chest doi: 10.1378/chest.126.6.1783 – volume: 46 start-page: 2568 year: 2008 end-page: 2572 ident: B24 article-title: In vitro survey of triazole cross-resistance among more than 700 clinical isolates of Aspergillus species publication-title: J Clin Microbiol doi: 10.1128/JCM.00535-08 – volume: 57 start-page: 3380 year: 2013 end-page: 3387 ident: B13 article-title: Population-based survey of filamentous fungi and antifungal resistance in Spain (FILPOP Study) publication-title: Antimicrob Agents Chemother doi: 10.1128/AAC.00383-13 – volume: 52 start-page: 3633 year: 2014 end-page: 3640 ident: B5 article-title: Cryptic and rare Aspergillus species in Brazil: prevalence in clinical samples and in vitro susceptibility to triazoles publication-title: J Clin Microbiol doi: 10.1128/JCM.01582-14 – volume: 47 start-page: 3138 year: 2009 end-page: 3141 ident: B3 article-title: Molecular identification of Aspergillus species collected for the Transplant-Associated Infection Surveillance Network publication-title: J Clin Microbiol doi: 10.1128/JCM.01070-09 – volume: 178 start-page: 427 year: 2014 end-page: 433 ident: B7 article-title: Antifungal susceptibility profile of cryptic species of Aspergillus publication-title: Mycopathologia doi: 10.1007/s11046-014-9775-z – year: 2008 ident: B11 publication-title: CLSI. reference method for broth dilution antifungal susceptibility testing of filamentous fungi; approved standard ;(2nd ed) ;CLSI document M38-A2 ;Clinical and Laboratory Standards Institute, Wayne, PA – volume: 9 start-page: 1656 year: 2018 ident: B14 article-title: Aspergillus species and antifungals susceptibility in clinical setting in the north of Portugal: cryptic species and emerging azoles resistance in A. fumigatus publication-title: Front Microbiol doi: 10.3389/fmicb.2018.01656 – volume: 56 start-page: 501 year: 2018 end-page: 505 ident: B6 article-title: Antifungal susceptibilities to amphotericin B, triazoles and echinocandins of 77 clinical isolates of cryptic Aspergillus species in multicenter surveillance in Korea publication-title: Med Mycol doi: 10.1093/mmy/myx067 – volume: 25 start-page: 307 year: 2019 end-page: 310 ident: B8 article-title: Successful treatment of invasive pulmonary aspergillosis caused by Aspergillus felis, a cryptic species within the Aspergillus section Fumigati: A case report publication-title: J Infect Chemother doi: 10.1016/j.jiac.2018.10.016 – volume: 56 start-page: 584 year: 2012 end-page: 587 ident: B18 article-title: Antifungal susceptibilities of Aspergillus fumigatus clinical isolates obtained in Nagasaki, Japan publication-title: Antimicrob Agents Chemother doi: 10.1128/AAC.05394-11 – volume: 4 start-page: 625 year: 2005 end-page: 632 ident: B10 article-title: Aspergillus lentulus sp. nov., a new sibling species of A. fumigatus publication-title: Eukaryot Cell doi: 10.1128/EC.4.3.625-632.2005 – volume: 106 start-page: 2641 year: 2005 end-page: 2645 ident: B20 article-title: Improved outcome in central nervous system aspergillosis, using voriconazole treatment publication-title: Blood doi: 10.1182/blood-2005-02-0733 – volume: 65 start-page: 2116 year: 2010 end-page: 2118 ident: B15 article-title: Azole antifungal resistance in Aspergillus fumigatus: 2008 and 2009 publication-title: J Antimicrob Chemother doi: 10.1093/jac/dkq279 – volume: 63 start-page: 1283 year: 2020 end-page: 1298 ident: B4 article-title: Rare/cryptic Aspergillus species infections and importance of antifungal susceptibility testing publication-title: Mycoses doi: 10.1111/myc.13158 |
SSID | ssj0006590 |
Score | 2.423076 |
Snippet | There are few reports on the clinical course of proven invasive aspergillosis (IA) due to rare/cryptic species in allogeneic hematopoietic stem cell transplant... |
SourceID | pubmedcentral proquest asm2 pubmed crossref |
SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source |
StartPage | e0163021 |
SubjectTerms | Epidemiology and Surveillance Mycology |
Title | Clinical and Microbiological Characteristics of Proven Invasive Aspergillosis Due to Rare/Cryptic Species in Allogeneic Hematopoietic Stem Cell Transplant Recipients |
URI | https://www.ncbi.nlm.nih.gov/pubmed/34780271 https://journals.asm.org/doi/10.1128/AAC.01630-21 https://www.proquest.com/docview/2598075771 https://pubmed.ncbi.nlm.nih.gov/PMC8765323 |
Volume | 66 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bb9MwFLbGEIgXBOU2bjII9rJlS537Y1WYJqaiMXXS9hTZibtGa5OqSR7K_-H38Jc4x86tHZMGL1FlH6Vuzxf72Dnfdwj55Lix23edvmFxuNgQ0RpiYgZGJExvgpJatkC-8-i7e3xuf7twLra2fneylspCHEQ__8or-R-vQhv4FVmy_-DZ5qbQAJ_Bv3AFD8P1Tj4e1rRGlS2RNJpKqm24IcWMyW7LDOY21NbgKmt9gDLhV8lslqEsyZdSldE443gsfTRcrhYo5qoK1Kusrb0BGMJYJLQeo9RrtsgSqWwKOd8b4img1kqfgbswIE0WSS0V1SjdpkUy1yPFcV8pgp3i1k3lvGKDNaf8l3zO5xUT52yV5eV1A8OTBDpU4DsqUwl906TBbs7TzBhlmkN_WV63PUKfw_OcT5Nl1j3xYJg6YlSTdEsywNmvk9fa-Y-7UygEVIbt6wLHB1JP8aig6jq6jm69BujKL12s31xaGNIlBoPhAUTJlmloYveGWHfddY_cZ7BvwZIaJz9a-Xr4Ws2JqoZVMzGYf9i9MYQHPJ-z9VDpxv5nM423ExeNn5DH1YaGDjQ6n5ItmfbIA13idNUjD0dV8kaP7J5qmfTVPh23rL98n-7S01ZAffWM_KpxTQEYdAPXdAPXNJtQjWta45qu4ZoCrmmRUcT1YYVqWqGaJiltUU3XUE0R1RRRTVtU0xbVz8n50dfx8NioyokY3PbtwnD7IsBTTseMWGwLLxDc8fEYts-FB4G8EK4bmwHjsGSxeGJx3xRmHDtMTnzmy8B6QbbTLJWvCGUmdwMrEIrDIyeW7_kRE1HkxNLuRzzYIR_RgWE1V-Sh2mozPwQvh8rLIevvkL3avWFUCfJjXZjZLdafG-uFFqK5xe5DjZQQVgp8_cdTmZV5yJwAlcc9D2xeauQ0d7JszzcZ9nhrmGoMUIV-vSdNpkqNHsIpx2LW67v85DfkUftAvyXbxbKU7yCoL8R79aD8AaiS_pQ |
linkProvider | Colorado Alliance of Research Libraries |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Clinical+and+Microbiological+Characteristics+of+Proven+Invasive+Aspergillosis+Due+to+Rare%2FCryptic+Species+in+Allogeneic+Hematopoietic+Stem+Cell+Transplant+Recipients&rft.jtitle=Antimicrobial+agents+and+chemotherapy&rft.au=Yamamuro%2C+Ryosuke&rft.au=Kimura%2C+Muneyoshi&rft.au=Asano-Mori%2C+Yuki&rft.au=Abe%2C+Masahiro&rft.date=2022-01-18&rft.pub=American+Society+for+Microbiology&rft.issn=0066-4804&rft.eissn=1098-6596&rft.volume=66&rft.issue=1&rft_id=info:doi/10.1128%2FAAC.01630-21&rft.externalDocID=01630-21 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0066-4804&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0066-4804&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0066-4804&client=summon |